Bioptim for Research

Risk of Acute Rejection Evaluation

The urinary chemokines CXCL9 and CXCL10 are promising noninvasive diagnostic markers of acute rejection (AR) in kidney recipients, but their levels might be confounded by urinary tract infection (UTI) and BK-virus reactivation. Multiparametric model development and validation addressed these confounding factors in a training set of 391 samples, optimizing the diagnostic performance of urinary chemokines. […]

Decision curve analyses demonstrated the clinical utility of the model. Considering confounding factors rather than excluding them, we optimized a noninvasive multiparametric diagnostic model for AR of kidney allografts with unprecedented accuracy.

Tinel C, Devresse A, Vermorel A, et al. Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. Am J Transplant. 2020;20:3462–3476.

Données cliniques

Birthdate Sample Date Sex

Male Female

Données sanguines

eGFR CKD-EPI or Creatinine ⓘ

HLA-DSA ⓘ

Oui Non

HLA-DSA MFI [optional]

Luminex Supplier [optional]

Immucor One Lambda

BK Virus DNAemia ⓘ

Oui Non

BK Virus Viral Load [optional]

Données urinaires

Urinary Tract Infection ⓘ

Oui Non

Urine Creatinine ⓘ

uCXCL9 ⓘ

uCXCL10 ⓘ

Probabilité de rejet aigu

Pas encore calculée

Risk of Acute Rejection Evaluation

Données cliniques

Données sanguines

Données urinaires

Probabilité de rejet aigu

Bioptim for Research, coded and hosted by Sêmeia.